New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing to its existing Moderna Technology Center ("MTC") in Norwood, Massachusetts. Through this strategic onsh ...

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December 2nd at 11:00am ET A live webcast of each of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com. ...

Core Insights - Moderna's stock has experienced a five-day winning streak, resulting in a total gain of 13% and an increase in market capitalization by approximately $1.2 billion, bringing it to around $10 billion [1][3] - Despite the recent gains, the stock remains 35.8% lower than its value at the end of 2024, while the S&P 500 has year-to-date returns of 16.5% [1][3] Financial Performance - The recent performance surge was driven by a Q3 earnings beat, with an EPS of -$0.51, which significantly surpassed forecasts, indicating improved cost management and operational efficiency [3] - Moderna has reduced its 2025 operating expense outlook by $700 million, reflecting tighter financial discipline and enhanced long-term profitability potential [3] Market Sentiment - The momentum from the winning streak may indicate increasing investor confidence, potentially leading to follow-on purchases [4] - However, there are concerns regarding Moderna's overall weak operating performance and financial state, which may not be fully reflected in its moderate valuation [5] Company Overview - Moderna specializes in mRNA-based therapies and vaccines targeting infectious diseases, immuno-oncology, rare conditions, cardiovascular issues, and autoimmune diseases, with a portfolio of 44 programs, including 26 clinical trials across seven modalities [6]

Summary of Moderna's Extraordinary General Meeting Company Overview - **Company**: Moderna, Inc. (NasdaqGS:MRNA) - **Event**: 2025 Extraordinary General Meeting - **Date**: November 12, 2025 Key Points Meeting Structure and Procedures - The meeting was chaired by Noubar Afeyan, Chairman of the Board, with CEO Stéphane Bancel and Chief Legal Officer Shannon Klinger present [1][2] - A quorum was confirmed with proxies received for a majority of the shares outstanding as of the record date, September 30, 2025 [4] - Voting was conducted via proxy and virtual ballot, allowing shareholders to change their votes if desired [5] Proposals Discussed - **Proposal One**: Approval of a one-time stock option exchange program for non-executive committee employees - The Board of Directors unanimously recommended approval of this proposal [8] - **Proposal Two**: Approval to adjourn the special meeting to a later date if necessary - The Board also unanimously recommended approval of this proposal [8] Voting Results - Both proposals received the requisite number of votes in favor and were approved by shareholders [10] - Since Proposal One was approved, there was no need to adjourn the meeting [10] - Final voting results will be reported on Form 8-K to be filed with the SEC within four business days [11] Additional Notes - No shareholder questions relevant to the business of the special meeting were received in advance [12] - The meeting concluded with a note of appreciation for shareholder support [12]

Group 1 - Barclays has lowered the target price for Moderna from $31 to $25 while maintaining a "hold" rating [1]

Group 1: Q3 Earnings Overview - The Q3 earnings season has started positively, with 91% of S&P 500 companies reporting results, and analysts expect a 13.1% increase in earnings per share, marking the fourth consecutive quarter of double-digit growth [2][9] - Initial expectations were lower, with analysts predicting a 7.9% increase in earnings per share as of September 30 [3] - Companies have reported more positive earnings surprises (82%) than negative ones (18%), with 77% of companies also reporting positive revenue surprises [9] Group 2: Notable Company Earnings - Instacart reported GAAP earnings per share of $0.51, exceeding estimates of $0.50, with revenue of $939 million, surpassing expectations of $933 million [6] - Constellation Energy's stock fell nearly 6% after reporting GAAP earnings per share of $2.97, missing estimates of $3.05, although revenue of $6.57 billion exceeded expectations [12] - Wendy's reported revenue of $549 million, a 3% decline year-over-year but above estimates of $534 million, with earnings per share of $0.24 beating expectations of $0.20 [16][17] - Block's shares fell 15% after reporting earnings per share of $0.54 on revenue of $6.11 billion, missing estimates of $0.68 per share and $6.31 billion in revenue [23] - Airbnb's stock rose 5% as it reported 133.6 million nights booked, a 9% increase year-over-year, driven by international bookings [32][33] Group 3: Industry Trends and Challenges - The earnings growth rate for Q3 is on track to increase from Q2, driven by tech enthusiasm around artificial intelligence and ongoing tariff concerns [10] - Consumer-facing companies are experiencing pressures from affordability and sentiment, with mentions of government shutdown impacts increasing [11] - Under Armour reported a net loss of $0.04 per share, with revenue declining 4.7% year-over-year, attributed to challenging consumer demand [35][36]

Geopolitical Tensions in Energy Sector - Lukoil has declared force majeure at Iraq's West Qurna-2 oilfield due to complications from Western sanctions, leading Iraq to freeze all payments to Lukoil [3][8] - Iraq is exploring legal avenues to maintain operations at West Qurna-2, which has initial recoverable reserves of approximately 14 billion barrels, with Lukoil holding a 75% stake [3][8] Strategic Resource Partnerships - China has formalized a partnership with Chile to allow direct participation in lithium production, significantly impacting the global lithium supply chain, as Chile holds over 52% of the world's lithium reserves and accounts for 30% of global output [4][8] Semiconductor Industry Developments - German officials have welcomed the resumption of Nexperia chip deliveries, alleviating concerns about chip supply chain disruptions affecting sectors like automotive manufacturing [5][8] Analyst Ratings and Corporate Acquisitions - Citi has raised Nvidia's short-term price target to $220 from $210, indicating continued confidence in the company's trajectory [6][8] - BofA Global Research has downgraded Moderna's price objective to $21 from $24, reflecting a more cautious outlook on the biotech company's prospects [6][8] - Investindustrial is nearing a deal to acquire TreeHouse Foods for approximately $3 billion, highlighting ongoing M&A activity in the food processing sector [7][8]

Core Viewpoint - Wall Street major averages experienced weekly losses due to struggles in the AI-tech trade, lower consumer sentiment, and the ongoing U.S. government shutdown [1] Market Performance - The Nasdaq index declined by 3% week to date [1] - The S&P 500 index fell by 1.6% week to date [1]

Core Insights - Moderna reported Q3 CY2025 revenue of $1.02 billion, a 45.4% year-on-year decline, but exceeded Wall Street expectations by 32% [1][6] - The company's full-year revenue guidance was lowered to $1.8 billion, 4.4% below analysts' estimates [1][6] - GAAP loss per share was $0.51, significantly better than the consensus estimate of -$2.38, representing a 78.6% beat [1][6] Financial Performance - Revenue: $1.02 billion vs analyst estimates of $769.6 million, reflecting a 45.4% decline year-on-year [6] - EPS (GAAP): -$0.51 vs analyst estimates of -$2.38, a 78.6% beat [6] - Adjusted EBITDA: -$208 million vs analyst estimates of -$911.9 million, indicating a 77.2% beat [6] - Operating Margin: -25.6%, down from -3.8% in the same quarter last year [6] - Market Capitalization: $9.50 billion [6] Management Commentary - Management attributed the outperformance to cost discipline, with a 34% reduction in combined costs compared to last year [3][5] - Future growth is expected to rely on expanding the commercial portfolio, particularly in respiratory and oncology segments [4] - The company aims to reach cash breakeven by 2028 through revenue growth and further cost reductions [4]

Core Insights - Moderna reported a revenue of $1.02 billion for the quarter ended September 2025, which is a decrease of 45.4% compared to the same period last year [1] - The earnings per share (EPS) was -$0.51, a decline from $0.03 in the year-ago quarter, but it exceeded the consensus EPS estimate of -$2.15 by 76.28% [1] - The revenue surpassed the Zacks Consensus Estimate of $860.07 million by 18.13% [1] Revenue Breakdown - Product sales in the Rest of the World were $175 million, falling short of the estimated $196.36 million, representing a 46% decline year-over-year [4] - Product sales in the United States reached $782 million, exceeding the average estimate of $499.39 million, but still reflecting a 35.6% decrease from the previous year [4] - Net product sales totaled $973 million, surpassing the estimated $835.12 million, marking a 46.5% decline year-over-year [4] - Other revenue amounted to $43 million, exceeding the average estimate of $25.19 million, showing a year-over-year increase of 2.4% [4] - Grant revenue within other revenue was $14 million, significantly higher than the estimated $5.56 million, indicating a 100% increase compared to the year-ago quarter [4] Stock Performance - Over the past month, Moderna's shares have declined by 15.6%, while the Zacks S&P 500 composite increased by 1.3% [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]